Dr. Mustafa Diken received his Ph.D. in tumor immunology from Johannes Gutenberg University, Mainz and is currently serving as the Deputy Director of Immunotherapy Development Center at TRON and the Deputy Vice President of Immunotherapies Department at Biontech RNA Pharmaceuticals. His research focuses on the development of novel cancer vaccines based on antigen-encoding messenger RNA (mRNA) and the elucidation of immunomodulatory mechanisms for cancer immunotherapy. His other scientific interests include assay development for preclinical testing of cancer vaccines. Dr. Diken is also the scientific secretary of the Association for Cancer Immunotherapy (CIMT), a non-profit organization aimed at advancing cancer immunotherapy.
Visit the Tron page
Read Carl June's publication on Protein corona–mediated targeting of nanocarriers to B cells allows redirection of allergic immune responses